Resources with keywords: paxlovid
Important Updates on COVID-19 Therapeutics for Treatment and Prevention (Website, Regulatory)
CDC HAN
20 December 2022
The majority of Omicron sublineages circulating in the United States have reduced susceptibility to the monoclonal antibody, bebtelovimab and the monoclonal antibody combination, cilgavimab and tixagevimab (EvusheldTM). Antiviral therapeutics for the treatment of COVID-19, ritonavir-boosted nirmatrelvir (Paxlovid™), remdesivir (Veklury®), and molnupiravir (Lagevrio™), retain activity against currently circulating Omicron sublineages.
Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022 (Website, Publication, Regulatory)
CDC/MMWR
2 December 2022
Shah MM, Joyce B, Plumb ID, et al.
New COVID-19 Test to Treat Initiative and Locator Tool (Website, Regulatory)
CDC/Clinician Outreach and Communication Activity (COCA)
A new way to get tested for Covid and treated at the same site, if appropriate. People who test positive at home can also bring those tests to the sites to be evaluated for treatment.
